PhaseFolio
Sign in

For BD and diligence work

Your question, as a landscape you can cite.

Atlas, the PhaseFolio app, lists the registered studies that match your question, one row per study across public trial registries. Every value links to the record it came from, and where records disagree the row says so.

Sign up for AtlasOpen an example dataset
Example dataset · Oncology52 studies

Which registered studies name datopotamab deruxtecan as an intervention?

6 of the 52 studies in Datopotamab deruxtecan studies, one row per study
StudySponsorConditionPhase and status
NCT07720284AstraZenecaHigh-risk Muscle Invasive Urothelial CarcinomaPhase 3Recruiting
NCT07291037AstraZenecaNon-small Cell Lung Cancer (NSCLC)Phase 3Recruiting
NCT01042379QuantumLeap Healthcare CollaborativeHER2-negative Breast CancerPhase 2Recruiting
NCT07825753Fudan UniversityAdvanced or Metastatic Pancreatic AdenocarcinomaPhase 2Not yet recruiting
NCT06244485Also in CTISDaiichi SankyoAdvanced Solid TumorPhase 1Active, not recruiting
NCT05117476Also in CTISCullinan Therapeutics Inc.NSCLCPhase 1Active, not recruiting

6 of 52 studies, data as of 9 Oct 2026. Each cell shows the first value the dataset gives; the full table lists the rest. In 23 of the 52 studies, registry records disagree on phase, status, enrolment, start or primary completion. Sources: ClinicalTrials.gov; EU Clinical Trials Information System (CTIS); EU Clinical Trials Register (EudraCT). See all 52 studies

In Atlas

What you can open in Atlas today.

Atlas is the PhaseFolio app for searching studies, companies and drugs.

  1. A landscape for your question

    Ask in your own words. Atlas lists the matching studies, one row per study across the trial registries. Then switch the view: the studies, companies by phase, or primary completion dates.

  2. A page for each company and drug

    A company page shows the studies it leads by condition and phase. A drug page lists the companies, conditions and studies that name it, with its FDA and EMA records. Where Atlas reads a company’s SEC filings, the company page adds the agreements and press releases in them, and a drug page adds those that name the drug.

  3. A slide and a file to hand on

    Print the Slide view or save it as a PDF. Export CSV or Excel with the question, the criteria, the data-as-of date and a link from every row to its registry record.

Companies by phase, counted by lead sponsor

CompanyAll studiesPhase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Not reported
AstraZenecaRegistered in 4 spellings2715501510
Daiichi SankyoRegistered in 5 spellings93012201
Fudan University20020000
Medical University of ViennaRegistered in 2 spellings20020000
Four of the 20 rows in the Companies view of the example dataset Datopotamab deruxtecan studies (52 studies), the four with the most studies. A 0 means no study in this dataset at that phase; it says nothing about studies these search terms did not find. Data as of 9 Oct 2026. Open the example
See how Atlas works

Saved in Atlas

A saved dataset keeps its question, criteria and date.

Each cell names the registry record and field it was read from.

Move it to newer data and Atlas makes a new version and lists what each registry changed, study by study.

See how Atlas works

The platform

Many sources, joined where the records link them.

PhaseFolio links public trial registries, regulatory records, company filings and other sources into one picture of each company and drug: its trials, pipeline, regulatory history, events and deals. Every value stays attached to the record it came from.

Trials
Records for one trial in different registries become one study where they carry each other’s trial numbers.
Companies
For each company PhaseFolio has reviewed, every spelling its review accepted counts as one company.
Drugs
A drug’s other names, where a company filing states them, are listed beside it, and where a filing states two names as one program, PhaseFolio can group them into one program row.

Where registry records for one trial disagree, PhaseFolio says so and shows each with its source. None is overwritten.

ClinicalTrials.govNCT05104866Active, not recruitingCTIS2023-509631-37-00Start, EU/EEA 2022-01-18EUCTR2020-005620-128 country recordsBEDEESFRHUITNLPLOne study, ten recordsNCT051048663 registries, 8 countriesRecruitment statusClinicalTrials.govActive, not recruitingEUCTR NLCompletedBoth kept as stated.Neither is picked.
Data as of 6 Oct 2026. Sources: ClinicalTrials.gov, CTIS, EU Clinical Trials Register.
  • 640,000+Registered studiesOne row per study, joined from more than 730,000 records in ClinicalTrials.gov, CTIS and the EU Clinical Trials Register.
  • 5.1 million+Values in shared categoriesPhase, recruitment status, study type, countries and more, each linked to the registry record it was read from.
  • 29,000+FDA applicationsFrom Drugs@FDA, with more than 51,000 products, their holders, marketing status and approval dates.
  • 2,300+EU medicinesFrom the EMA medicines catalogue, with each medicine's status, holder and dated events.

Counts are rounded down. Trial registry data as of 5 Nov 2026; FDA and EMA catalogues as captured on 4 Nov 2026.

  • Trials

    Registered studies from public trial registries: phase, status, design, sponsors, countries and dates, one row per study.

  • Companies

    One page per reviewed company: every accepted spelling of its name, and the studies that name it as sponsor or collaborator.

  • Drugs and pipelines

    Each drug with its conditions and studies, and the programs company filings tie to it under a target PhaseFolio has reviewed.

  • Approvals

    Regulators’ own catalogues: applications, products, holders, marketing status and approval dates, as each regulator states them.

  • Deals and news

    Agreements and press releases from company filings, each quoted as filed, dated and linked to its filing.

  • Every value cited

    Each value names the record it came from, under a data-as-of date. What a record does not report is marked missing, not filled in.

When records disagree

Read what the record says. Then check it.

One Phase 3 study, ten registry records. ClinicalTrials.gov states it is active, not recruiting.1 The Netherlands record in the EU Clinical Trials Register states completed.2 Six other country records give a status PhaseFolio does not map, and keep the reason: the trial transitioned to the Clinical Trials Regulation.3 CTIS status is not collected yet, and PhaseFolio says so.4

PhaseFolio matches the ten records to one study, says where they disagree and keeps every statement with its record and field. None is overwritten, for this or any other kind of fact.

NCT05104866 · 10 records · data as of 6 Oct 2026

Recruitment status, every statement

Active, not recruitingClinicalTrials.govOverall Recruitment Status
CompletedEUCTR NLTrial Status
Not mappedrecord_transitioned_to_ctrEUCTR BE, DE, FR, HU, IT, PLTrial Status
Not mappedongoing_recruitment_not_statedEUCTR ESTrial Status
Not collected yetCTISNot read in this release

Also captured for this study

Identifiers
NCT, EU CT, EudraCT and sponsor protocol numbers
Sponsors
11 names, as each record writes them
Phase and authorization
Every record's statement, mapped
Key dates
40 dates, by record and jurisdiction
Enrollment
Actual and planned, by scope
Conditions
33 terms, with MeSH and MedDRA codes as given
Interventions
137 terms: names, INNs and CAS numbers

Shown as stated, each with its source. None overwritten or reworded.Sources: ClinicalTrials.gov; EU Clinical Trials Register (EudraCT); EU Clinical Trials Information System (CTIS).

Notes

  1. ClinicalTrials.gov, NCT05104866, field Overall Recruitment Status. Value normalized to PhaseFolio’s status taxonomy. Last update posted 24 Aug 2026; PhaseFolio data as of 6 Oct 2026. View the record
  2. EU Clinical Trials Register, 2020-005620-12, Netherlands record, field Trial Status. Value normalized to PhaseFolio’s status taxonomy. PhaseFolio data as of 6 Oct 2026. View the record
  3. EU Clinical Trials Register, 2020-005620-12, records for Belgium, France, Germany, Hungary, Italy and Poland, field Trial Status. Not mapped, reason code record_transitioned_to_ctr. View the Belgian record
  4. EU Clinical Trials Information System (CTIS), 2023-509631-37-00. This release does not yet read recruitment status from CTIS. View the record

Sources

The public record, source by source.

Each source is listed with its status, live in Atlas or planned.

Live in Atlas

See every source and its status

Planned sources

Not yet connected in Atlas. Shown as planned, without dates.
  • RORResearch Organization Registry identifiersPlanned
  • GLEIFLegal entity identifiers and company groupsPlanned
  • Company websites and newswiresAnnouncements a company publishes outside its SEC filingsPlanned
  • PubMedPublication records and citationsPlanned
  • Open TargetsTarget and disease contextPlanned
  • ChEMBLMolecules and mechanismsPlanned

Coverage expands as each source becomes available in Atlas.

Start with your next question.

Sign upContact sales